Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tibulizumab - Zura Bio

Next Previous
Drug Profile

Tibulizumab - Zura Bio

Alternative Names: Anti-BAFF IL-17A monoclonal antibody - Eli Lilly and Company; BAFF/IL-17A-Eli-Lilly and Company; LY-3090106; ZB-106

Latest Information Update: 02 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Zura Bio
  • Class Anti-inflammatories; Antirheumatics; Bispecific antibodies; Skin disorder therapies; Small molecules
  • Mechanism of Action B cell activating factor inhibitors; Interleukin 17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa; Systemic scleroderma
  • Phase I Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 29 Jun 2026 Zura Bio completes enrollment in the phase II TibuSHIELD trial for Hidradenitis suppurativa in USA, Canada, Germany, Hungary, Poland (SC)
  • 29 Jun 2026 Zura Bio plans a phase II trial for Immunological disorders (SC) by year end 2026
  • 20 May 2025 Phase-II clinical trials in Hidradenitis suppurativa in Canada (SC) (NCT06993610)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top